Investing.com -- 专注于G蛋白偶联受体(GPCR)药物发现的生物技术公司Septerna, Inc. (NASDAQ:SEPN)在报告第二季度净亏损扩大的情况下,尽管盈利表现好于预期,其股价仍下跌了4.3%。 这家临床阶段生物技术公司报告第二季度调整后每股亏损为-$0.56,比分析师预估的-$0.63好$0.07。季度收入为10万美元。公司净亏损从去年同期的1640万美元扩大到...
Source LinkInvesting.com -- 专注于G蛋白偶联受体(GPCR)药物发现的生物技术公司Septerna, Inc. (NASDAQ:SEPN)在报告第二季度净亏损扩大的情况下,尽管盈利表现好于预期,其股价仍下跌了4.3%。 这家临床阶段生物技术公司报告第二季度调整后每股亏损为-$0.56,比分析师预估的-$0.63好$0.07。季度收入为10万美元。公司净亏损从去年同期的1640万美元扩大到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.